Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (28294)	2/21/1999 9:44:00 AM
From: Henry Niman	Respond to of 32384

Greg, I believe that licensing agreements can be signed NOW, since LGND already has TWO approved drugs for cancer (i.e. an Asian license could be written to include the sale of ONTAK, Oral and Topical Panretin, and Oral and Topical Targretin, plus whatever they come up with from ELN). Since Targretin oral and topical Targretin targets CTCL, as does the APPROVED drug ONTAK, a licensing deal to combine ALL of the CANCER drugs (approved and soon to be approved) would make sense. Just a LGND was looking to critical mass to hire a sales force, others might want a package from LGND so when they tell their customers about ONTAK and topical Panretin, they call also mention the other drugs that are being submitted to the FDA for FAST TRACK approval. And of course the license can include an up front payment NOW just as the LLY deal included up front payments for the rights to develop Targretin, LGD1268, and LGD1324 for metabolic diseases.

To: Abuckatatime who wrote (28294)	2/21/1999 9:49:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Greg, Think of it this way. If you were a Japanese pharmaceutical looking to sell ONTAK for CTCL on label, with the potential for generating significant off label sales for other lymphomas, would you want oral and topical Targretin included, with their potential on CTCL) and off label sales (Breast Cancer)? Look at LGND's deal with QLTIF to sell PHOTOFRIN in Canada. At the time it was just approved for superficial bladder cancer, but the agreement is for ALL indications, on or off label.